Unfortunately, with this depressing and counterproductive management for shareholders, we can only hope for a miracle.

Not even 30 million capitalization and the continuous constant dilution speak more than 1000 pr ..
There is no interest, we always exchange less than $ 100,000 a day, and worse, following the various pr of the last few years that have never been respected, Moscato has lost all credibility. The only news that could reverse the trend are:
- approval ind
- Ngio quotation at at least $ 5
- positive phase 1/2 results
- positive results phase 2b ae37
- start of profitability of the numerous subsidiaries / initiatives (excellagen / arizona etc.)
- cooperation / acquisition agreement with some big western pharma
- replacement of the CEO

the market had trusted Moscato, bringing the price in 2019 to over $ 3: lack of results, pr not respected, dilution did the rest ..